CELL A.T. aggiornamenti

Yvo60

Nuovo Utente
Sospeso dallo Staff
Registrato
11/3/03
Messaggi
637
Punti reazioni
61
da qui potro ' aggiornarvi di eventuali cambiamenti
per adesso cell positiva al primo segnale negativo o di ritracciamento pesante vi avviso
 
il long sta perdendo un po' di forza

piccolo ritracciamento in atto
forse per scaricare gli oscillatori
ricordate che chiusura sopra 1.64/1,65 dara' un segnale long multiday
 
Bene yvo.......... ;)
 
Yvo60 ha scritto:
da qui potro ' aggiornarvi di eventuali cambiamenti
per adesso cell positiva al primo segnale negativo o di ritracciamento pesante vi avviso

:)
 
mi aspetto almeno un OK da chi mi segue

altrimenti mi sembra di parlare da solo.............grazie
 
Cell !!!!!!

Se Puo' Servire Qualche Giorno Fa In Una Clinica Di Pavia Nella Sezione Di Oncologia Alcuni Medici Parlavano Di Cellììììì.
Cercherò Notizie Approfondite E Le Postero'. Ok!
 
Yvo60 ha scritto:
altrimenti mi sembra di parlare da solo.............grazie
ok e grazie trovo interessanti i tuoi interventi OK!
 
avanti tutta con gli aggiornamenti , ti seguiamo!!!
 
Allora Vi Aggiorno Un Po'

Io Alle 13,30 Vi Lascio Devo Andare In Ufficio

Ricordatevi Due Cose

Io Restero' Long Con Una Chiusura Sopra 1,64/1,65
Se Parte Okkio Tra 1,694 E 1,705 Se Passa Va Di Corsa
Al Test Di 1,75

Chiusura Sopra 1,75 Titolo Super Long

Segnali Di Oscillatori Tutti Positivi

Quindi Calma E Niente Scalper Oggi
 
Raga' a parte l'AT che non guasta mi sembra la stessa giornata di Settembre:tutta la mattinata sempre in salita e senza scossoni in discesa :yes:
 
Azz E Che So Un Magoooo

Ehehehehehe 1,705 Testato

Mo Calma E Sangue Freddo
 
Yvo60 ha scritto:
Ehehehehehe 1,705 Testato

Mo Calma E Sangue Freddo

Bravo. OK!

Io,intanto acquistato un po di Eurotech a 9.1 con stop a 9 e take profit a 9.3
 
Yvo60 ha scritto:
Io Alle 13,30 Vi Lascio Devo Andare In Ufficio

Ricordatevi Due Cose

Io Restero' Long Con Una Chiusura Sopra 1,64/1,65
Se Parte Okkio Tra 1,694 E 1,705 Se Passa Va Di Corsa
Al Test Di 1,75

Chiusura Sopra 1,75 Titolo Super Long

Segnali Di Oscillatori Tutti Positivi

Quindi Calma E Niente Scalper Oggi


Concordo con la tua analisi!! :clap: :clap: :clap:

Speriamo che chiuda bene sopra 1,75 o che almeno tenga bene il supporto a 1,705... Credo che l'apertura a NY sarà il punto di svolta della giornata... chiaramente imho!
 
Cell Therapeutics, Inc. (CTI) Reports 2005 Fourth Quarter and Year End Results
SEATTLE, March 9 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) reported financial results for the quarter and year ended December 31, 2005. Total revenues for the quarter were $1.2 million compared to $8.1 million in the fourth quarter of 2004. CTI reported a net loss for the quarter of $18.7 million ($0.27 per share) compared to a net loss of $43.5 million ($0.72 per share) for the same period in 2004. This included a $40.7 million gain in the quarter on the divestiture of TRISENOX(R) and a $23.6 million charge for the conversion of $38.4 million related to the Company's 4% and 5.75% convertible senior subordinated notes.

Total revenues for the year ended December 31, 2005, were $16.1 million compared to $29.6 million in 2004. For the year, CTI posted a net loss of $102.5 million ($1.59 per share), including a $71.2 million gain for the year on the divestiture of TRISENOX, compared to a net loss of $252.3 million ($4.67 per share) in 2004, which included an $87.4 million charge related to in-process research and development resulting from the acquisition of Novuspharma S.p.A..

Revenues for the quarter and year ended December 31, 2005 were lower as compared to the same periods in 2004 due to a reduction in product sales revenues as a result of the divestiture of TRISENOX to Cephalon in July 2005. The Company ended the year with cash, cash equivalents, securities available-for-sale and interest receivable of approximately $69 million. This amount excludes proceeds of $24.6 million held in escrow until April 30, 2006 to fund potential redemptions of 30% of the 6.75% convertible senior notes.

As of February 28, 2006, $56.1 million of the 6.75% convertible senior notes had converted into approximately 21.3 million shares. As a result of the conversions we paid make whole interest of $18.9 million.

"Our efforts to reduce expenses and raise additional capital over the last several months have placed us in the position this year to focus on advancing XYOTAX(TM) toward marketing applications in the United States and Europe and on reporting the interim analysis for the pixantrone phase III trial in non-Hodgkin's lymphoma," stated James A. Bianco, M.D., President and CEO of CTI.

2005 Highlights

-- Completed an $82 million convertible senior notes offering and
conversion of $38.4 million of outstanding 5.75% and 4% convertible
senior subordinated notes

-- Announced that pixantrone achieved the primary endpoint of a
randomized trial, significantly prolonging time to progression when
added to rituximab compared to rituximab alone, in indolent
non-Hodgkin's lymphoma

-- Reported gender specific survival benefit observed in STELLAR 3 and
4 trials among women on XYOTAX, linking survival benefit to estrogen
status and metabolism of polymer

-- Reported prospective analysis of phase II trial (PGT202)
demonstrating estrogen-linked survival benefit for women with
non-small cell lung cancer on XYOTAX

-- Initiated first gender specific approval trial (PIONEER trial) in
non-small cell lung cancer

-- Significantly reduced operating costs compared to 2004 and refocused
resources on near term XYOTAX and pixantrone milestones

-- Completed the divestiture of TRISENOX to Cephalon, and recorded a
$71.2 million gain for the year, with the potential to earn an
additional $100 million in milestones

-- Appointed Stonefield Josephson, Inc. as independent registered public
accounting firm

-- Appointed John Bauer, former Nintendo of America, Inc. Executive Vice
President of Finance, as new board member and Chair of the Company's
Audit Committee and appointed Phil Nudelman as Chairman of the Board

-- Announced initiation by the Gynecologic Oncology Group (GOG) of a
large phase III clinical trial examining the ability of XYOTAX to
maintain remission and prolong the survival of ovarian
cancer patients

-- Announced XYOTAX patent allowance in Japan, which will provide
exclusivity until 2018; announced that the European Patent Office
issued an allowance for a patent directed to XYOTAX, which when
issued, will have the same term as existing U.S. patents that provide
patent protection for XYOTAX until 2017
 
La 50 e l'RSI sopra il top per ora non ce fanno 'n baffo OK!
 
Allora Io Sto Per Andare

Seguite Cell A Vista D'okkio
Il Segnale Che Sto Avendo E' Uguale Al Candelone Di Settembre
Quindi Navigate A Vista Senza Fare Scalper

Il Mio Stop E' Sempre Una Chiusura Sotto 1,64/1,65

Non So Cosa Puo' Succedere All'apertura Dell'america Ma Un Segnale Cosi' Forte Non Lo Si Vedeva Da Tempo

Buon Lavoro A Tutti E Ci Sentiamo Alle 20,00 Per Programmare Domani
 
Indietro